STOCK TITAN

I:SPX Oct 2023 Weekly 3100.000 - INFI STOCK NEWS

Welcome to our dedicated page for I:SPX Oct 2023 Weekly 3100.000 news (Ticker: INFI), a resource for investors and traders seeking the latest updates and insights on I:SPX Oct 2023 Weekly 3100.000 stock.

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing, and delivering best-in-class medicines for the treatment of challenging diseases, with a particular focus on oncology and inflammation. The company harnesses its robust small molecule discovery and development capabilities to address unmet medical needs.

Infinity's research and development programs stem from the integration of a broad spectrum of scientific expertise, including cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. This multidisciplinary approach enables the company to innovate and advance its pipeline of potential therapies effectively.

Strategic Alliances
Infinity Pharmaceuticals has established substantial partnerships with leading pharmaceutical and biotechnology companies. These alliances are crucial in maximizing the potential of Infinity's product pipeline, allowing the company to leverage external expertise and resources in its quest to bring new treatments to market.

Business and Scientific Expertise
The company's team is composed of passionate, committed, and innovative professionals who bring together a wealth of experience in various fields. This collective expertise is pivotal in driving the company's mission forward, from early-stage research to clinical development and commercialization.

Infinity Pharmaceuticals continuously updates its stakeholders and the public with the latest news and developments. Keeping abreast of these updates is essential for anyone interested in the company's progress and its impact on the pharmaceutical landscape.

-
Rhea-AI Summary
MEI Pharma and Infinity Pharmaceuticals will host a joint video webcast on June 19, 2023, to provide an update on their pending merger and an overview of the combined company. The webcast will feature presentations from executive management and discussions with experts in oncology treatment. The combined company's pipeline includes three clinical-stage oncology drug candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Infinity Pharmaceuticals (NASDAQ: INFI) has announced upcoming presentations on eganelisib, an innovative immuno-oncology therapy, at the 2023 American Association of Cancer Research (AACR) Annual Meeting from April 14-19 in Orlando, Florida. Highlights include preclinical data indicating that PI3K-γ inhibition can convert tumor-associated macrophages in head and neck squamous cell carcinoma and non-small cell lung cancer into activated immune-stimulating cells. Presentation details include sessions by Professor Judith A. Varner of UCSD Moores Cancer Center, focusing on the clinical implications of targeting myeloid cells in cancer. The ongoing MARIO-275 and MARIO-3 trials show promising results in systemic immune activation and tumor microenvironment reprogramming with eganelisib combined with other therapies, reinforcing its potential as a next-generation immunotherapeutic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
conferences
Rhea-AI Summary

Infinity Pharmaceuticals reported its 2022 financial results, ending the year with cash and cash equivalents of $38.3 million, down from $80.7 million in 2021. The company incurred a net loss of $44.4 million in 2022, slightly less than the $45.3 million loss in 2021. Infinity is in the process of merging with MEI Pharma, an agreement expected to close mid-2023, which may provide a combined cash balance of approximately $100 million. The merger aims to advance three clinical oncology candidates, including eganelisib, which will focus on head and neck cancer treatments. However, if the merger fails, Infinity's cash runway could end by mid-2023, necessitating potential strategic alternatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

MEI Pharma and Infinity Pharmaceuticals have announced a merger agreement to create a combined company that will focus on advancing a diverse clinical-stage oncology pipeline. This includes three drug candidates: eganelisib, voruciclib, and ME-344, targeting various cancers. The merger is expected to be an all-stock transaction, with projected cash balance of approximately $100 million to fund operations through mid-2025. MEI shareholders are expected to own 58% and Infinity shareholders 42% of the new entity. The merger seeks to leverage combined expertise and resources to enhance therapeutic options for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Infinity Pharmaceuticals (NASDAQ: INFI) announced its participation in the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022, in New York. CEO Adelene Perkins will lead a fireside chat on November 29 at 4:00 p.m. ET, discussing the company’s lead product, eganelisib, an innovative oral immuno-oncology treatment for cancer. Investors can attend 1-on-1 meetings with Infinity representatives. A replay of the presentation will be available on Infinity's website for 90 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
conferences
Rhea-AI Summary

Infinity Pharmaceuticals reported a 52% increase in one-year progression-free survival in its MARIO-3 study for eganelisib in front-line TNBC patients, compared to the Impassion130 benchmark. The company aims to announce a partnership to advance eganelisib's development in Q1 2023. Financially, Infinity has $47.2 million in cash as of Q3 2022, down from $80.7 million at the end of 2021. The net loss for Q3 2022 remains unchanged at $10.7 million, with expected net losses for the year between $40 million and $50 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.82%
Tags
-
Rhea-AI Summary

Infinity Pharmaceuticals reported promising results from its MARIO-3 study of eganelisib in combination with atezolizumab and nab-paclitaxel for treating front-line metastatic triple negative breast cancer (TNBC). The study showed a 52% increase in one-year progression-free survival (PFS) rates compared to the IMpassion130 benchmark. A total of 62 patients were enrolled, with a median follow-up of 10.0 months. No new safety signals were found, and the treatment profile remained consistent with expectations. This data supports earlier findings regarding eganelisib's potential to improve long-term patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.82%
Tags
none
-
Rhea-AI Summary

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on November 14, 2022, at 8:30 AM ET to discuss its third-quarter financial results. The company is focused on developing eganelisib, an innovative oral therapeutic aimed at reprogramming macrophages in cancer treatment. Clinical studies are underway, including MARIO-3, which examines eganelisib combined with Tecentriq® and Abraxane® in front-line advanced cancer patients, and MARIO-275, focused on urothelial cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
Rhea-AI Summary

Infinity Pharmaceuticals (NASDAQ: INFI) announced its participation in two major investor conferences. The Wells Fargo Healthcare Conference will take place on September 9, 2022, featuring a presentation by CEO Adelene Perkins at 8:00 a.m. ET. The H.C. Wainwright Global Investment Conference is set for September 12, 2022, with a virtual presentation available at 7:00 a.m. ET. Infinity is focused on developing eganelisib, an innovative therapeutic targeting immune suppression in cancer. Presentations can be accessed for 90 days post-event on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.52%
Tags
conferences

FAQ

What is the market cap of I:SPX Oct 2023 Weekly 3100.000 (INFI)?

The market cap of I:SPX Oct 2023 Weekly 3100.000 (INFI) is approximately 726.1K.

What is the primary focus of Infinity Pharmaceuticals?

Infinity Pharmaceuticals focuses on discovering, developing, and delivering best-in-class medicines for oncology and inflammation.

What capabilities does Infinity Pharmaceuticals possess?

Infinity has strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation.

Who are Infinity Pharmaceuticals' strategic partners?

Infinity has alliances with leading pharmaceutical and biotechnology companies to advance its product pipeline.

What is the mission of Infinity Pharmaceuticals?

The mission is to discover, develop, and deliver to patients best-in-class medicines for difficult-to-treat diseases.

What makes Infinity Pharmaceuticals unique?

Its multidisciplinary approach and strong focus on small molecule discovery and development make it unique.

What areas of expertise does the Infinity team bring together?

The team brings together expertise in business and scientific fields, including cancer biology and medicinal chemistry.

How does Infinity Pharmaceuticals contribute to the pharmaceutical field?

By innovating and advancing its pipeline of potential therapies for challenging diseases.

Where can I get the latest updates about Infinity Pharmaceuticals?

The latest updates can be found on their official communications and financial news websites.

What types of diseases is Infinity Pharmaceuticals targeting?

The company targets difficult-to-treat diseases, with a strong focus on oncology and inflammation.

Why are strategic alliances important for Infinity Pharmaceuticals?

Alliances help Infinity leverage external expertise and resources to realize the full potential of its product pipeline.

I:SPX Oct 2023 Weekly 3100.000

Nasdaq:INFI

INFI Rankings

INFI Stock Data

726.09k
81.91M
2.36%
23.49%
2.43%
Biotechnology
Healthcare
Link
United States
Cambridge